The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Leadership - Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
 
Helen J. Ross
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Spectrum Pharmaceuticals (Inst)
 
David E. Kozono
Honoraria - Reflexion Medical
 
James John Urbanic
No Relationships to Disclose
 
Terence Marques Williams
Speakers' Bureau - MJH Healthcare Holdings, LLC
Research Funding - Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent pending on the development of novel chemotherapies based on work from my lab. The provisional application was submitted June 2018. However, we are abandoning our application.
Travel, Accommodations, Expenses - Varian Medical Systems
 
Carter DuFrane
No Relationships to Disclose
 
Ilze Bara
No Relationships to Disclose
 
Katja Schulze
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Research Funding - Genentech
 
Jane Michelle Brockman
Employment - Genentech
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Genentech
 
Xiaofei F. Wang
No Relationships to Disclose
 
Junheng Gao
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Honoraria - Abbvie; Ascendis Pharma (I); AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Takeda (I)
Consulting or Advisory Role - Abbvie; Ascendis Pharma (I); AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Takeda (I)
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Lilly (Inst); Novartis
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Foundation Medicine; Genentech/Roche; Janssen Oncology; Lilly; Medtronic; Novartis; Pfizer; Puma Biotechnology; Regeneron; Takeda
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Regeneron (Inst); Takeda (Inst)